StockData
Curanex Pharmaceuticals Inc logo

Curanex Pharmaceuticals Inc (CURX) company profile

CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$4.70+0.07 (+1.40%)

Close on Nov 17, 2026Market cap $7.37MP/E –Yield –

About Curanex Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Curanex Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing botanical medicines for patients with inflammatory diseases. The company's lead drug candidate is Phyto-N, a proprietary botanical extract derived from a medicinal plant used in traditional Chinese medicine. Curanex is advancing a development pipeline targeting six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with its primary development focus on ulcerative colitis.

The company operates as a single corporate entity without subsidiaries and conducts its nonclinical research across partner academic and research institutions. Its planned Phase 1 clinical development is scheduled to take place in Australia following regulatory clearances. Curanex Pharmaceuticals is incorporated in Nevada and maintains its principal executive offices in Jericho, New York.

Summary of the business section of Curanex Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Curanex Pharmaceuticals Inc
Founded
2018
Headquarters
Jericho, NY
Address
2 Jericho Plaza,, Suite101b 11753
Phone
(718) 673-6078
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
Kreit & Chiu CPA LLP, Los Angeles, California

Stock & identifiers

Ticker
CURX
Exchange
Nasdaq
IPO date
Aug 26, 2025
Shares outstanding
31M, Aug 14, 2026
Filer category
<br>Emerging growth company
Stock splits
1-for-20 reverse, Aug 20, 2026
SEC CIK
2025942
FIGI
BBG01QB818N7
Share class FIGI
BBG01QB818P5
EIN
83-0741390

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jun LiuCEO and President, Director10,524,560
Huijuan ZhongChief Science Officer, Director–
Ning ZhangChief Technology Officer–
Dian Ying JingSecretary4,651,000
Liqin XieChief Operating Officer–
Xiaohui HaoDirector–
Yong YanDirector–
Helen Hong HsuDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 26, 2025
Offer price
$4.00
Securities offered
3,750,000
Gross proceeds
$15.00M
Exchange
Nasdaq
First trading day
Aug 26, 2025
First-day close
$4.02+0.5%
Lock-up ends (est.)
Feb 22, 2026

“Per Share Total Initial public offering price $ 4.00 $ 15,000,000 Underwriting discounts and commissions (1) $ 0.28 $ 1,050,000 Proceeds to us (before expenses) (2) $ 3.72 $ 13,950,000 (1) The Company has agreed to pay the underwriters a fee equal to 7% of the gross proceeds of the offering.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?